Exact Sciences Corporation
NASDAQ•EXAS
CEO: Mr. Kevin T. Conroy J.D.
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2001-02-01
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Contact Information
Market Cap
$19.80B
P/E (TTM)
-94.6
19.8
Dividend Yield
--
52W High
$103.75
52W Low
$38.81
52W Range
Rank62Top 92.6%
1.9
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 1.9 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$878.38M+0.00%
4-Quarter Trend
EPS
-$0.45+0.00%
4-Quarter Trend
FCF
$120.45M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Total Revenue Grew 17.7% Total revenue reached $3.25B USD in 2025, driven by 20.2% growth in Screening revenue segment.
Net Loss Significantly Narrowed Net loss reduced to $207.9M USD in 2025, a substantial improvement from $1.03B USD loss last year.
Operating Cash Flow Improved Cash provided by operating activities was $491.4M USD, reflecting a $280.9M USD improvement over 2024.
Abbott Merger Agreement Signed Entered Merger Agreement with Abbott for $105.00 cash per share; expected consummation in Q2 2026.
Risk Factors
Merger Execution Uncertainty Failure or delay in closing the Abbott Merger could materially affect operations and common stock price.
Dependence on Product Success Success heavily relies on commercialization of Screening and Precision Oncology tests in development pipeline.
Regulatory and Reimbursement Risks Uncertainty exists related to healthcare reform, pricing, coverage, and maintaining adequate reimbursement rates.
Need for Additional Capital Additional capital may be required to fully fund strategic plan; financing availability or terms are uncertain.
Outlook
Productivity Plan Implementation Implementing multi-year productivity plan targeting over $150M USD in expected annual savings by 2026.
Pipeline Development Investment Expect continued significant investment in R&D to enhance current products and advance pipeline offerings.
Next-Generation MRD Test Launch Plan to introduce next-generation Oncodetect MRD test leveraging MAESTRO technology in 2026.
International Expansion Exploration Exploring opportunities to make Cologuard and Cancerguard tests available outside the U.S. market soon.
Peer Comparison
Revenue (TTM)
$14.30B
$11.24B
$8.10B
Gross Margin (Latest Quarter)
96.1%
90.0%
89.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ROIV | $21.13B | -25.4 | -18.3% | 4.0% |
| EXAS | $19.80B | -94.6 | -8.5% | 43.0% |
| RVMD | $19.78B | -16.8 | -63.1% | 6.7% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
7.5%
Steady Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data